T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dollar General
DG
|
+$1.37B |
| 2 |
Intel
INTC
|
+$1.28B |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$1B |
| 4 |
Nike
NKE
|
+$859M |
| 5 |
Uber
UBER
|
+$825M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.67B |
| 2 |
Amazon
AMZN
|
+$2.15B |
| 3 |
NVIDIA
NVDA
|
+$1.64B |
| 4 |
Humana
HUM
|
+$1.57B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$1.33B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.09% |
| 2 | Healthcare | 15.81% |
| 3 | Financials | 11.13% |
| 4 | Consumer Discretionary | 10.82% |
| 5 | Communication Services | 8.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Nucor
NUE
$61.7B
| $366M | 0.05% |
2,102,912
+28,290
| +1% | +$4.49M |
|
302
Boston Scientific
BSX
$74.5B
| $364M | 0.05% |
6,303,756
+516,386
| +9% | +$27.6M |
|
303
Vulcan Materials
VMC
$36.3B
| $364M | 0.05% |
1,605,175
-51,944
| -3% | -$11M |
|
304
Bristol-Myers Squibb
BMY
$130B
| $364M | 0.05% |
7,086,056
+401,783
| +6% | +$21.1M |
|
305
Quest Diagnostics
DGX
$26.2B
| $359M | 0.05% |
2,604,158
+396,447
| +18% | +$52.1M |
|
306
Loews
L
$23.1B
| $359M | 0.05% |
5,158,505
-253,928
| -5% | -$16.9M |
|
307
RenaissanceRe
RNR
$13.2B
| $358M | 0.05% |
1,828,988
-288,887
| -14% | -$60.1M |
|
308
Textron
TXT
$15.3B
| $358M | 0.05% |
4,451,717
-32,355
| -0.7% | -$2.51M |
|
309
Veralto
VLTO
$23.6B
| $356M | 0.05% |
4,326,836
+4,161,115
| +2,511% | +$311M |
|
310
Steris
STE
$23.1B
| $356M | 0.05% |
1,618,014
+85,305
| +6% | +$18M |
|
311
Vale
VALE
$61.4B
| $353M | 0.05% |
22,286,695
+21,526,055
| +2,830% | +$309M |
|
312
Popular Inc
BPOP
$11.2B
| $352M | 0.05% |
4,289,731
-356,035
| -8% | -$25.2M |
|
|
CFLT
313
DELISTED
Confluent
CFLT
| $351M | 0.05% |
14,994,745
+3,870,881
| +35% | +$93.5M |
|
314
Microchip Technology
MCHP
$43.1B
| $348M | 0.05% |
3,853,717
-193,185
| -5% | -$15.7M |
|
315
RPM International
RPM
$14.7B
| $345M | 0.05% |
3,088,606
-199,066
| -6% | -$20.1M |
|
|
ONC
316
BeOne Medicines Ltd
ONC
$40.6B
| $344M | 0.05% |
1,908,189
+158,624
| +9% | +$28.7M |
|
317
Nu Holdings
NU
$65.5B
| $343M | 0.05% |
41,224,713
-13,720,599
| -25% | -$111M |
|
318
Charles River Laboratories
CRL
$13.6B
| $341M | 0.05% |
1,443,175
-237,498
| -14% | -$46.7M |
|
|
SUM
319
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
| $339M | 0.05% |
8,814,270
+3,339,736
| +61% | +$116M |
|
320
Insmed
INSM
$28.9B
| $334M | 0.04% |
10,763,771
+356,555
| +3% | +$9.25M |
|
321
Caterpillar
CAT
$393B
| $333M | 0.04% |
1,124,920
-654,583
| -37% | -$170M |
|
322
Ralph Lauren
RL
$23.6B
| $326M | 0.04% |
2,263,164
-55,584
| -2% | -$6.88M |
|
323
Burlington
BURL
$22.3B
| $325M | 0.04% |
1,672,007
+125,082
| +8% | +$18.7M |
|
324
Novanta
NOVT
$6.32B
| $325M | 0.04% |
1,927,689
+849,703
| +79% | +$124M |
|
325
Zscaler
ZS
$28.7B
| $321M | 0.04% |
1,450,145
+5,796
| +0.4% | +$1.07M |
|
Similar funds
T. Rowe Price Associates's Q4 2023 Portfolio in Review
As of Q4 2023, T. Rowe Price Associates held 2,974 positions worth $744B, up 9.1% from $682B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates's Q4 2023 filing shows 92 new, 1,834 increased, 805 reduced and 67 closed positions. Its largest new stake was Canadian Natural Resources: 6,473,658 shares worth $212M. The largest sale was Microsoft, an estimated $2.67B.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q4 2023 buy was Canadian Natural Resources: 6,473,658 shares worth $212M.
- T. Rowe Price Associates added most to Dollar General in Q4 2023, an estimated $1.37B increase.
- T. Rowe Price Associates's biggest Q4 2023 reduction was Microsoft, cutting an estimated $2.67B.
- T. Rowe Price Associates fully exited Activision Blizzard in Q4 2023, selling an estimated $293M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $744B portfolio in Q4 2023.
- T. Rowe Price Associates opened 92 new positions and closed 67 in Q4 2023.
- T. Rowe Price Associates's portfolio value rose 9.1% quarter-over-quarter to $744B.
Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.